SK287810B6 - Farmaceutický prostriedok obsahujúci nízkodávkovú kombináciu metformínu a glyburidu - Google Patents

Farmaceutický prostriedok obsahujúci nízkodávkovú kombináciu metformínu a glyburidu Download PDF

Info

Publication number
SK287810B6
SK287810B6 SK500-2002A SK5002002A SK287810B6 SK 287810 B6 SK287810 B6 SK 287810B6 SK 5002002 A SK5002002 A SK 5002002A SK 287810 B6 SK287810 B6 SK 287810B6
Authority
SK
Slovakia
Prior art keywords
metformin
glyburide
dose
combination
diabetes
Prior art date
Application number
SK500-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK5002002A3 (en
Inventor
Beth Anne Piper
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SK5002002A3 publication Critical patent/SK5002002A3/sk
Publication of SK287810B6 publication Critical patent/SK287810B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK500-2002A 1999-11-03 2000-10-13 Farmaceutický prostriedok obsahujúci nízkodávkovú kombináciu metformínu a glyburidu SK287810B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes
PCT/US2000/028311 WO2001032157A2 (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and glibenclamide

Publications (2)

Publication Number Publication Date
SK5002002A3 SK5002002A3 (en) 2004-05-04
SK287810B6 true SK287810B6 (sk) 2011-10-04

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
SK500-2002A SK287810B6 (sk) 1999-11-03 2000-10-13 Farmaceutický prostriedok obsahujúci nízkodávkovú kombináciu metformínu a glyburidu

Country Status (23)

Country Link
EP (1) EP1229918B1 (is)
JP (1) JP5183844B2 (is)
KR (1) KR20070089259A (is)
CN (1) CN1450902A (is)
AR (1) AR026356A1 (is)
AT (1) ATE390140T1 (is)
AU (1) AU780106B2 (is)
BR (1) BR0015294A (is)
CA (1) CA2389928C (is)
EE (1) EE05260B1 (is)
HU (1) HU229352B1 (is)
IL (1) IL149139A0 (is)
LT (1) LT5058B (is)
LV (1) LV12910B (is)
MX (1) MXPA02004282A (is)
NO (1) NO330026B1 (is)
NZ (1) NZ518278A (is)
PL (1) PL199278B1 (is)
RU (1) RU2275915C2 (is)
SK (1) SK287810B6 (is)
TW (1) TWI280125B (is)
UY (1) UY26424A1 (is)
WO (1) WO2001032157A2 (is)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
WO2005046687A1 (en) * 2003-10-30 2005-05-26 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
EP1696897B1 (en) * 2003-12-19 2011-07-06 Omega Bio-Pharma (I.P.3) Limited Compositions for treating diabetes
BRPI0510613A (pt) * 2004-05-03 2007-10-30 Omega Bio Pharma Ip3 Ltd cisteaminas para tratar complicações de hipercolesterolemia e diabete
ES2603879T3 (es) 2007-07-19 2017-03-01 Takeda Pharmaceutical Company Limited Preparación sólida que comprende alogliptina e hidrocloruro de metformina
UA105480C2 (uk) 2007-09-10 2014-05-26 Янссен Фармацевтика Н.В. Спосіб одержання сполук, які застосовують як інгібітори натрійзалежного переносника глюкози
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
ES2596291T3 (es) 2010-05-11 2017-01-05 Janssen Pharmaceutica, N.V. Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
AU2012213435B2 (en) * 2011-02-02 2017-03-30 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX2017007699A (es) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
DE122007000054I1 (de) 1997-06-18 2007-12-13 Smithkline Beecham Plc Behandlung der Diabetes mit Thiazolidindione und metformin
JP4278863B2 (ja) * 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
PT974356E (pt) * 1998-07-15 2004-02-27 Merck Sante Sas Comprimidos compreendendo uma combinacao de metformina e de glibenclamida
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
MXPA02004282A (es) 2003-02-17
NO20022087D0 (no) 2002-05-02
LT2002063A (en) 2003-06-25
BR0015294A (pt) 2003-07-15
LT5058B (lt) 2003-09-25
JP2003519621A (ja) 2003-06-24
EP1229918A2 (en) 2002-08-14
IL149139A0 (en) 2002-11-10
HU229352B1 (en) 2013-11-28
AR026356A1 (es) 2003-02-05
PL199278B1 (pl) 2008-09-30
WO2001032157A3 (en) 2002-01-24
JP5183844B2 (ja) 2013-04-17
HUP0300218A2 (hu) 2003-06-28
LV12910B (en) 2003-05-20
NO20022087L (no) 2002-06-24
AU780106B2 (en) 2005-03-03
CA2389928C (en) 2010-03-23
TWI280125B (en) 2007-05-01
PL364885A1 (en) 2004-12-27
RU2002114820A (ru) 2004-03-10
CN1450902A (zh) 2003-10-22
HUP0300218A3 (en) 2006-02-28
NZ518278A (en) 2004-10-29
ATE390140T1 (de) 2008-04-15
EP1229918B1 (en) 2008-03-26
AU1082601A (en) 2001-05-14
EE200200242A (et) 2003-12-15
NO330026B1 (no) 2011-02-07
CA2389928A1 (en) 2001-05-10
RU2275915C2 (ru) 2006-05-10
UY26424A1 (es) 2001-05-31
SK5002002A3 (en) 2004-05-04
EE05260B1 (et) 2010-02-15
WO2001032157A2 (en) 2001-05-10
KR20070089259A (ko) 2007-08-30

Similar Documents

Publication Publication Date Title
US7598262B2 (en) Method for treating diabetes
SK287810B6 (sk) Farmaceutický prostriedok obsahujúci nízkodávkovú kombináciu metformínu a glyburidu
JP2003519621A5 (is)
AU8022900B2 (is)

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20201013